OCTAGAM 5% SOLUCIÓN PARA INFUSIÓN INTRAVENOSA Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

octagam 5% solución para infusión intravenosa

octapharma ag - proteÍna total (imunoglobulina g humana polivalente ≥ 95%) - proteÍna total (imunoglobulina g humana polivalente ≥ 95%)....50 mg.

Respreeza European Union - English - EMA (European Medicines Agency)

respreeza

csl behring gmbh - alpha1-proteinase inhibitor (human) - genetic diseases, inborn, lung diseases - antihemorrhagics, - respreeza is indicated for maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor deficiency (e.g. genotypes pizz, piz(null), pi(null,null), pisz). patients are to be under optimal pharmacologic and non-pharmacologic treatment and show evidence of progressive lung disease (e.g. lower forced expiratory volume per second (fev1) predicted, impaired walking capacity or increased number of exacerbations) as evaluated by a healthcare professional experienced in the treatment of alpha1-proteinase inhibitor deficiency.,

HEPATECT CP Israel - English - Ministry of Health

hepatect cp

kamada ltd, israel - human hepatitis b immunoglobulin - solution for infusion - human hepatitis b immunoglobulin 50 mg / 1 ml - immunoglobulins, normal human, for intravascular adm. - immunoglobulins, normal human, for intravascular adm. - prophylaxis against hepatitis b in adults and children over 2 years of age who have not been vaccinated against hepatitis b (including persons whose vaccination is incomplete or missing) who are at risk of infection with hepatitis b by accidental contact with hepatitis b virus containing material following: - percutaneous exposure (e.g. accidental needle stick). - direct mucous membrane contact. when the administration of an intramuscular hepatitis b immunoglobulin is not possible. the immunoglobulin should be administered in association with hepatitis b vaccine. prophylaxis against re-infection of a transplanted liver in patients who carry the surface antigen of the hepatitis b virus. immunoprophylaxis of hepatitis b in the newborn of a hepatitis b virus carrier mother.

CSL ZOSTER IMMUNOGLOBULIN VF (human) 200IU injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

csl zoster immunoglobulin vf (human) 200iu injection vial

csl behring australia pty ltd - human immunoglobulin g, quantity: 160 mg/ml; zoster immunoglobulin, quantity: 200 iu - injection, solution - excipient ingredients: water for injections; glycine; human immunoglobulin a - indications as at 8 august 2002 : zoster immunoglobulin is indicated for prophylaxis against varicella in patients who meet all four of the criteria listed below: 1. one of the following underlying illnesses or conditions: a. neoplastic disease (leukaemia or lymphoma); b. congenital or acquired immunodeficiency; c. immunosuppressive therapy with steroids or antimetabolites. 2. one of the following types of exposure to chickenpox or shingles patients: a. household contact; b. playmate contact (>1 hour play indoors); c. hospital contact (in same 2 to 4 bedroom or adjacent beds in a large ward); d. newborn contact (newborn of mother who had onset of chickenpox <5 days before delivery or within 48 hours after delivery); e. premature infant (>= 28 weeks gestation) whose mother lacks a prior history of chickenpox; f. premature infant (< 28 weeks gestation or <= 1000g) regardless of maternal history. 3. negative or unknown history of chickenpox. 4. if zoster immunoglobulin can be administered within 96 hours after exposure. zoster immunoglobulin, normal immunoglobulin (immunoglobulin for intramuscular use) or plasma are of no value in the treatment of established varicella or zoster infection. high levels of circulating antibody do not prevent dissemination of infection. zoster immunoglobulin is not indicated for prophylactic use in immunodeficient children or adults when there is a history of varicella, unless the patient's immunosuppressed status is that which is associated with bone marrow transplantation.

Human Rabies Immunoglobulin Malta - English - Medicines Authority

human rabies immunoglobulin

bio products laboratory limited dagger lane, elstree hertfordshire, wd6 3bx, united kingdom - immunoglobulin rabies, human - solution for injection - immunoglobulin rabies, human 150 iu/ml - immune sera and immunoglobulins

Human Hepatitis B Immunoglobulin Malta - English - Medicines Authority

human hepatitis b immunoglobulin

bio products laboratory limited dagger lane, elstree hertfordshire, wd6 3bx, united kingdom - immunoglobulin antihepatitis - solution for injection - immunoglobulin antihepatitis b 100 iu/ml - immune sera and immunoglobulins

GUNA-ANTI IL 1- anti-interleukin-1.alpha. immunoglobulin g rabbit- canakinumab solution/ drops United States - English - NLM (National Library of Medicine)

guna-anti il 1- anti-interleukin-1.alpha. immunoglobulin g rabbit- canakinumab solution/ drops

guna spa - anti-interleukin-1.alpha. immunoglobulin g rabbit (unii: ml4qrz1hcl) (anti-interleukin-1.alpha. immunoglobulin g rabbit - unii:ml4qrz1hcl), canakinumab (unii: 37cq2c7x93) (canakinumab - unii:37cq2c7x93) - anti-interleukin-1.alpha. immunoglobulin g rabbit 4 [hp_c] in 30 ml - anti interleukin 1 alpha      4c    acute pain and fever relief anti interleukin 1 beta        4c     acute pain and fever relief temporary relief of: - acute pain - fever take 15 minutes before meals.